Mindgram and PharmaTell Announce Partnership to Bring Premium Broker Research to Biopharma Teams

WASHINGTON, D.C. and AMERSFOORT, NETHERLANDS – October 1, 2026 – Mindgram Technologies, Inc., an AI research platform for the biopharmaceutical industry, and PharmaTell B.V., a provider of healthcare equity research since 2003, today announced a partnership to integrate PharmaTell’s library of broker research and forecast models into the Mindgram platform. Under the agreement, Mindgram’s biopharmaceutical clients may search and download PharmaTell research alongside their existing data sources and analyze it using Mindgram’s industry leading workflow solutions including the Mindgram Workbook, SmartGrid, Deep Research and Agent.

“Broker research is one of the richest sources of independent analysis on drug programs and pipelines, and I am thrilled to add PharmaTell to the corpus of Mindgram premium content,” said Shrey Verma, Founder and CEO, Mindgram. “Decisions have always been driven by solid data, extensive research and thoughtful analysis and this partnership elevates Mindgram’s ability to help clients with all three.”

PharmaTell’s broker research and forecast models are incorporated into the Data Foundation layer of Mindgram’s three-layer intelligence stack. Mindgram’s Knowledge Graph layer links the research to the relevant drugs, targets, companies and indications, and the AI Workflows layer enables structured and complex analysis of the combined data.

Partnership highlights

• Organization-wide access. Broker research is commonly licensed on a named-user basis and priced per page or per download, which restricts access to a limited number of research professionals. PharmaTell content is not subject to individual entitlements and is available to all Corporate Mindgram users within a client organization under a single subscription.
• Forecast models and industry intelligence. Clients also receive access to the company and drug forecast models underlying the research, as well as PharmaTell’s industry intelligence reports.
• Unlimited usage. PharmaTell reports may be viewed, downloaded and analyzed without per-page charges or monthly download fees.

“I have worked with broker research my entire career and have a deep appreciation for the depth of research and knowledge that goes into each report,” said Michael Hay, Chief Strategy Officer, Mindgram. “Adding PharmaTell’s first class library of reports and models to the Mindgram platform continues to expand on our strategy of partnering with best-in-class content providers to deliver the most in-depth and meaningful insights to the industry.”

Analysis with the Mindgram Agent

The Mindgram Agent can query the complete PharmaTell library, eliminating the need for document-by-document review. It supports probability of technical and regulatory success (PTRS) analyses, therapeutic area forecasts and target product profile (TPP) assessments with citations linking each output to the underlying report or forecast model.

“Our purpose has always been to make high-quality broker research more accessible and valuable to the life sciences industry, helping teams make better-informed decisions and ultimately move the industry forward. Partnering with Mindgram takes that a significant step further by bringing our content directly into their clients’ AI-powered biopharma workflows,” said Janno Roele, Chief Executive Officer, PharmaTell.

Availability

PharmaTell content is available immediately to Mindgram corporate clients. Demonstrations may be requested at www.mindgram.ai or by contacting Tyler Beatty, Head of Sales, at tbeatty@mindgram.ai.

About Mindgram

Mindgram Technologies, Inc. is an AI research platform for the biopharmaceutical industry. Founded in 2022 and headquartered in Washington, D.C., Mindgram operates a platform that integrates three layers: a Data Foundation of premium sources, a biopharma Knowledge Graph and AI Workflows. Together, these layers support cited analysis for competitive intelligence, conference coverage, clinical benchmarking, market forecasting and deep research. Mindgram’s clients include top 10 global pharmaceutical companies, investors and venture funds. For more information, visit www.mindgram.ai.

About PharmaTell

PharmaTell B.V., founded in 2003 and headquartered in Amersfoort, the Netherlands, provides healthcare equity research to the life sciences industry. Its curated library of broker research covers approximately 2,000 companies across biopharma, medtech, diagnostics, contract research and payers. PharmaTell delivers its research through PharmaTell Studio and its AI-powered EyesOn platform. For more information, visit www.pharmatell.com.

Media contacts

Mindgram
Michael Hay, Chief Strategy Officer
mhay@mindgram.ai

PharmaTell
Janno Roele, Chief Executive Officer
jroele@pharmatell.com